
Novaliq and Laboratoires Théa announce partnership and European Commission approval of ciclosporin 0.1% eye drops solution
Ciclosporin 0.1% eye drops solution will be marketed under the brand name Vevizye in the EU for the treatment of dry eye disease.
Novaliq and Laboratoires Théa announced European Commission approval of ciclosporin 0.1% eye drops solution (Vevizye) for the treatment of
Ciclosporin 0.1% eye drops solution was
Efficacy of Vevizye was shown in the ESSENCE-1 and ESSENCE-2 clinical trials. Both were randomized, multicenter, double-masked, vehicle-controlled studies with change from baseline in total corneal fluorescein staining (tCFS) score at Day 29 being the primary endpoint in both trials.
The ESSENCE-2 study included 834 patients with moderate to severe DED who were randomized to active treatment (n=423) or vehicle (n=411) following a 14-day run-in period during which they instilled an artificial tear twice daily. The patients instilled either cyclosporine or vehicle twice daily for 29 days and the results were compared.2
The study period ran from December 5, 2020, to October 8, 2021, at 27 US sites. The primary endpoints were the changes in the tCFS (0-15 [best to worst] on the National Eye Institute scale) and in the dryness score (0-100 [best to worst] on the visual analog scale) at day 29 compared with baseline. The investigators also evaluated the conjunctival staining, central corneal fluorescein staining, and the tCFS responders.2
Jean-Frédéric Chibret, President of the Théa Group, commented on the partnership in a press release from the companies stating,1 "Our partnership with Novaliq highlights our dedication to delivering innovative treatments to all patients. We are looking forward to launching Vevizye to complement our range of non-preserved treatments for dry eye, a disease that has substantial impacts on the quality of life of many patients."
Christian Roesky, PhD, CEO of Novaliq added by saying, "We are thrilled to partner with Théa, the leading ophthalmic pharmaceutical company in Europe, to bring Vevizye to patients.”
Vevizye is approved in all 27 EU member states.
References:
Novaliq and Laboratoires Théa Announce Partnership and EU Approval for Vevizye® (Ciclosporin 0.1% Eye Drops Solution). Press Release; October 2, 2024. Accessed October 2, 2024.
https://www.businesswire.com/news/home/20241002958802/en/Novaliq-and-Laboratoires-Th%C3%A9a-Announce-Partnership-and-EU-Approval-for-Vevizye%C2%AE-Ciclosporin-0.1-Eye-Drops-Solution FDA approves Novaliq’s cyclosporine ophthalmic solution for treatment of dry eye disease. June 8, 2023. Accessed October 2, 2024.
https://www.ophthalmologytimes.com/view/fda-approves-novaliq-s-cyclosporine-ophthalmic-solution-for-treatment-of-dry-eye-disease
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.